日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTIMA; KCSG GU20-03)

一项多中心 II 期研究,评估改良 FOLFIRINOX 方案一线治疗晚期脐尿管癌的疗效(ULTIMA;KCSG GU20-03)

Park, Inkeun; Lee, Jae Lyun; Yoon, Shinkyo; Shin, Sang Joon; Shin, Seong-Hoon; Kim, Jung Hoon; Park, Kwonoh; Lee, Hyo Jin

Molecular epidemiology and outcomes of EGFR exon 20 insertion in Korean patients with non-small cell lung cancer

韩国非小细胞肺癌患者EGFR 20号外显子插入的分子流行病学及预后

Yoon, Shinkyo; Kim, Seong-Eun; Lim, Sun Min; Jung, Hyun Ae; Kim, Kyu-Pyo; Kim, Dong-Kyu; Jeong, Hyehyun; Lim, Subin; Kim, Jung-Ae; Kim, Joohyun; Patel, Dony; Zhao, Xiahong; Yu, Dae Young; Kim, Ji Hyun; Lee, Dae Ho

MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines.

MED12 突变通过炎症细胞因子激活 MEK/ERK 通路,诱导 NSCLC 对 RTK 抑制剂产生耐药性

Ryu Hyun-Min, Kim Deokhoon, Choi Jun Young, Yoon Shinkyo, Lee Ho-Su, Park Ji Eun, Lee Eunjin, Sung Yunkyung, Lee Chang Hoon, Lee Eun-Young, Kim Wanlim, Seo Seyoung, Kim Sang-We, Park Kang-Seo, Lee Dae Ho

Vabametkib Treatment in Refractory Glioblastoma: A Case Report

Vabametkib治疗难治性胶质母细胞瘤:病例报告

Kim, Seong-Eun; Kim, Yongjae; Moon, Hye Hyeon; Nam, Soo Jeong; Park, Kang-Seo; Hong, Chang-Ki; Lee, Ho-Su; Yoon, Shinkyo; Park, Ji Eun

State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer

抗体药物偶联物治疗晚期膀胱癌的尖端成像技术

Eid, Sarah; Al-Yousef, Abdullah S; Kim, Kyung Won; Yoon, Shinkyo; Nawfal, Rashad; Bellmunt, Joaquim; Choueiri, Toni K; Krajewski, Katherine M

Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05)

培美曲塞维持治疗与观察治疗在完成一线铂类化疗且未出现疾病进展的晚期尿路上皮癌患者中的疗效比较(PREMIER,KCSG GU16-05)

Park, Inkeun; Yoon, Shinkyo; Kim, Ilhwan; Park, Kwonoh; Lee, Suee; Keam, Bhumsuk; Park, Joo-Hwan; Kim, Jin Young; Choi, Yoon Ji; Sohn, Byeong Seok; Lee, Jae Lyun

Exon-level TP53 alterations and PD-L1 expression identified by pretreatment NGS stratify survival in EGFR-mutant non-small cell lung cancer treated with first-line osimertinib

通过治疗前NGS检测发现的TP53外显子水平改变和PD-L1表达可对接受一线奥希替尼治疗的EGFR突变型非小细胞肺癌患者的生存期进行分层。

Kim, Seong-Eun; Kim, Yongjae; Yoon, Do Kyung; Park, Hwan; Park, Kang-Seo; Kim, Deokhoon; Hwang, Hee Sang; Ahn, Bokyung; Park, Ji Eun; Kim, Sang-We; Jang, Se Jin; Yoon, Shinkyo; Lee, Ho-Su; Lee, Dae Ho

Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma

晚期尿路上皮癌患者的身体成分和免疫治疗结果

Kim, Sojin; Yoon, Shinkyo; Park, Inkeun; Lee, Jae Lyun; Jeong, Hyehyun; Ko, Yousun; Kim, Kyung Won; Kim, Sun Young

Mapping tumor habitats in isocitrate dehydrogenase -wild type glioblastoma: Integrating MRI, pathologic, and RNA data from the Ivy Glioblastoma Atlas Project

绘制异柠檬酸脱氢酶野生型胶质母细胞瘤的肿瘤微环境图谱:整合来自常春藤胶质母细胞瘤图谱项目的MRI、病理和RNA数据

Park, Ji Eun; Oh, Joo Young; Park, Do Hoon; Lee, Ho-Su; Yoon, Shinkyo; Kim, NakYoung; Park, Seo Young; Song, Sang Woo; Kim, Young-Hoon; Hong, Chang-Ki; Kim, Jeong Hoon; Kim, Ho Sung

Epidemiology and Outcomes of Non-Small Cell Lung Cancer in South Korea

韩国非小细胞肺癌的流行病学和预后

Jung, Hyun Ae; Lee, Dae Ho; Lim, Sun Min; Yu, Hyeyeon; Yoon, Shinkyo; Kim, DongKyu; Kim, Kyu-Pyo; Jeong, Hyehyun; Doh, Haewon; Lim, Subin; Kim, Joohyun; Zhao, Xiahong; Horsburgh, David; Patel, Dony; Kim, Jung-Ae; Toh, Kong Chian